Corneodermatoosseous syndrome
(Redirected from CDO syndrome)
Corneodermatoosseous syndrome is a rare genetic disorder characterized by a combination of skin, bone, and eye abnormalities. This syndrome is also known as Corneodermatoosseous dysplasia.
Presentation[edit | edit source]
Individuals with Corneodermatoosseous syndrome typically present with a variety of symptoms that can affect multiple systems in the body. Common features include:
- Hyperkeratosis: Thickening of the outer layer of the skin.
- Osteosclerosis: Abnormal hardening of bone.
- Corneal opacities: Clouding of the cornea, which can affect vision.
- Skeletal abnormalities: These may include short stature, scoliosis, and other bone deformities.
Genetics[edit | edit source]
Corneodermatoosseous syndrome is believed to be inherited in an autosomal recessive manner. This means that an individual must inherit two copies of the defective gene, one from each parent, to be affected by the disorder. The specific gene or genes involved in this syndrome have not yet been identified.
Diagnosis[edit | edit source]
Diagnosis of Corneodermatoosseous syndrome is typically based on clinical evaluation and the presence of characteristic symptoms. Genetic testing may be used to confirm the diagnosis, especially if there is a known family history of the disorder.
Management[edit | edit source]
There is currently no cure for Corneodermatoosseous syndrome. Treatment is generally supportive and focuses on managing the symptoms. This may include:
- Dermatological treatments for skin abnormalities.
- Orthopedic interventions for skeletal deformities.
- Ophthalmological care for corneal opacities and other eye issues.
Prognosis[edit | edit source]
The prognosis for individuals with Corneodermatoosseous syndrome varies depending on the severity of the symptoms. Early diagnosis and appropriate management can improve the quality of life for affected individuals.
Related Pages[edit | edit source]
Categories[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD